Stimulant antigennegative differentiation of b-lymphocytes
(57) Abstract:The invention relates to medicine and medical industries and is the use of a peptide of the formula Tyr-Clu-Gly (L-tyrosyl-L-glutamyl-L-glycine) as a means of stimulating antigennegative the differentiation of b-lymphocytes. The invention consists in that as a means of stimulating antigennegative the differentiation of b-lymphocytes, using a synthetic peptide of structural formula: L-tyrosyl-L-glutamyl-L-glycine (Tyr-Glu-Gly). The invention is aimed at expanding Arsenal and increase biological activity funds, stimulating antigennegative the differentiation of b-lymphocytes. 3 table. The invention relates to medicine and medical industries and is the use of a peptide of the formula Tyr-Glu-Gly (L-tyrosyl-L-glutamyl-L-glycine) as a means of stimulating antigennegative differentiation of B-lymphocytes.Antigennegative differentiation of B-lymphocytes is a process of formation of functionally complete B-cells from precursor cells, which takes place on the territory of the Central organs of the immune system. Antigennegative differentiation end in the market, antigens CD21, CD22, and others), missing at early stages of development [1, 2]. One of the mechanisms of development of immunodeficiency in the B-system of immunity is oppression antigennegative differentiation of B-lymphocytes. Application in such cases, stimulants antigennegative differentiation may lead to normalization of immune status.The number of known substances that have the ability to stimulate antigennegative differentiation of B-lymphocytes. For the first time this property was described in extracts of the Central organs of the immune system - Bursa fabritsiusa birds and bone marrow of mammals. Famous works that describe how to extract from a fabric bag fabritsiusa birds, capable of stimulating antigennegative differentiation of B-lymphocytes, and represents a crude extract of animal raw materials, which was not isolated and identified the active principle [3, 4].Method acetic acid extraction from tissue bags fabritsiusa birds selected a substance that stimulates the maturation of B-lymphocytes , which is a complex of alkaline polypeptides with a molecular mass of from 2 to 12 KD belonging to the class of citomedines" and later called "burcelin". This GRE cells only at a concentration of 100 μg/ml [5, 6].Stimulants antigennegative differentiation of B-cells are hemolymphoreticular growth factors, obtained from the supernatant of the culture of bone marrow cells and being a protein with 110-140 MM KD, which gives additional substance allergogennym properties. In addition, this substance stimulates antigennegative differentiation of B-lymphocytes only at a concentration of from 5 to 10 mg/ml .The above substances are composed of a complex of peptides that can stimulate antigennegative differentiation of B-lymphocytes. Use them as drugs is difficult due to the complexity of the methods of preparation, low output active substances, considerable variability in their physical and chemical properties, and also because of the possibility of patients adverse reactions due to the presence of these drugs from the bag fabritsiusa and bone marrow ballast of high molecular weight components. It is preferable to use low molecular weight synthetic compounds. They are effective in extremely small doses, do not have allergogennym and toxic effects on the body.Known synthetic peptide, emerenciano B-lymphocytes  , manufactured under the brand name "bursin" (Sigma, Sweden). This means the technical essence and the achieved effect is closest to the proposed solution and its prototype.According to the prototype, a synthetic Tripeptide Lys-His-Gly-NH2dose-dependently and selectively stimulates the differentiation of precursor B cells into Mature B-cells, in other words stimulates antigennegative differentiation of B-lymphocytes, but does not affect T-cell differentiation. However, this peptide has low biological activity. Thus, the maximum activity of the substances is manifested in a concentration of 1 μg/ml in vitro and 1 mg/kg body weight at parenteral administration in vivo.The present invention is directed to expanding Arsenal and increase biological activity funds, stimulating antigennegative differentiation of B-lymphocytes.The solution of this problem is achieved by the fact that as a means of stimulating antigennegative differentiation of B-lymphocytes, are available to use synthetic peptide of structural formula L-tyrosyl-L-glutamyl-L-glycine (Tyr-Glu-Gly).The Tripeptide of the formula Tyr-Glu-Gly was found by us in tissue sumc Aravali solid-phase method, by building up the peptide chain to the N-end.In experimental study of the biological activity of the claimed substances identified its ability to stimulate antigennegative differentiation of B-lymphocytes.The specific activity of the proposed tool was assessed by the ability of the latter to cause the expression of differencirovannyh antigens are markers of Mature B-lymphocyte. The level of expression of differencirovannyh antigens was assessed by indirect membrane immunofluorescence using monoclonal antibodies (MCAT) LT21, LT22, and CH2 ("Sorbent", Moscow) to differentsirovannym antigens CD21, CD22 and IgM, which is a marker of Mature B-cell - final stage antigennegative differentiation of B-lymphocytes. The study was performed on lymphocytes of patients with burns, because you know that if you burn the sickness disturbed antigennegative differentiation of B-lymphocytes in peripheral blood is sharply reduced the number of Mature forms of B-cells [9, 10]. The peripheral blood lymphocytes of patients with burns IIIB - IV 15 - 30% of body surface were incubated for 2 hours at a temperature of 37oC in complete nutrient medium with the test tool in the concentration of the volume of saline. The obtained data are presented in tables 1 and 2.Found that patients with burns reduced the number of lymphocytes bearing surface IgM. The proposed peptide Tyr-Glu-Gly dose-dependently stimulates the expression of immunoglobulin receptors. Thus, the inventive agent is effective in concentrations of from 0.05 to 1 μg/ml, and the maximum activity was observed at concentrations of peptide concentration of 0.1 microgram/ml At the same time, a well-known tool bursin shows similar activity only at concentrations of 0.5-1 µg/ml Thus, the proposed tool is a synthetic peptide Tyr-Glu-Gly - increases the number of Mature B-lymphocytes bearing IgM receptors at doses 10 times smaller than the bursin.Found that patients with burns reduced the number of lymphocytes bearing markers of Mature B-lymphocyte CD21 and CD22. Incubation of lymphocytes burn patients with peptide Tyr-Glu-Gly leads to a significant increase in the number of CD21+and CD22+cells at a concentration of from 0.05 to 1 μg/ml, bringing these figures to normal, and the maximum activity of the peptide Tyr-Glu-Gly was observed in the concentration of 0.1 μg/ml At the same time, a well-known tool bursin manifests its activity only at concentrations of 0.5-1 µg/ml Thus, the peptide TyrP CLASS="ptx2">The specific biological activity of the inventive tool also studied in experiments in vivo in models of embryonic bursectomy. It is known that in the bag fabritsiusa is antigenetically differentiation of B-lymphocytes and its removal is accompanied by disruption of this process [6, 11]. However, there are marked inhibition of humoral immunity, which is associated with the lack bursectomised birds Mature B-lymphocytes that are able to be involved in the immune response. Bursectomised chickens significantly stunted and almost completely killed after 7-8 weeks of life.The embryonic bursectomy performed surgery on the 19th day of embryonic development, the control group of embryos at the same time subjected to a false operation playback of all stages of surgical intervention except for the removal of Bursa fabritsiusa.Since months of age during the week bursectomised Chicks intramuscularly received the peptide Tyr-Glu-Gly and bursin in doses of 0.01, 0.05, 0.1 and 1 mg/kg of body weight. The control were bursectomised chickens that received saline in the same volume.The number of Mature B-lymphocytes that have poverhnost chicken IgG-chain) and light chain immunoglobulins chicken ("Sigma", Sweden). It is known that Ig-receptors are differentsirovannym marker of B-cells and are determined by B-lymphocytes in the final stages antigennegative differentiation, but not in pre-B cells  . The results are shown in table 3.It is established that at the embryonic bursectomy Chicks sharply reduced the number of B-lymphocytes bearing surface Ig receptors , in particular membrane IgG. Introduction Tripeptide Tyr-Glu-Gly in doses from 0.01 to 1 mg/kg of body weight bursectomised birds leads to an increase in the number of Mature B-lymphocytes with Ig receptors on their surface, and the maximum activity of the peptide Tyr-Glu-Gly registered at a concentration of 0.1 mg/kg of body weight. A similar effect is achieved by the introduction Burkina in doses from 0.1 to 1 mg/kg, and the maximum activity Burkina is manifested in a concentration of 1 mg/kg of body weight of the chicken. Thus, the peptide Tyr-Glu-Gly stimulates antigennegative differentiation of B-lymphocytes at concentrations 10 times lower than the known peptide Lis-His-Gly-NH2.Bursectomised chickens due to impaired differentiation of B-lymphocytes significantly suppressed the humoral immune response develops l is antaviliai differentiation of B-cells, the increase in the number of functionally complete B-lymphocytes, resulting in normalization of the immune response, increasing the number of peripheral blood leukocytes, body weight, spleen and thymus.The results of experimental study of the proposed drug evidence of its high specific activity. The proposed synthetic peptide Tyr-Glu-Gly has a marked stimulating effect on the differentiation of B-lymphocytes. This is demonstrated in the following examples.Example 1. Synthetic peptide Tyr-Glu-Gly stimulates antigennegative differentiation of B-lymphocytes in vitro model of lymphocytes of patients with burns.The blood of patients with burns IIIB-IV degree 15-30% of the body surface stabilized with heparin (25 U/ml). Peripheral blood lymphocytes were isolated by density gradient ficoll-urografin (density of 1.077 g/ml). The number of cells in suspension when calculating the camera Goryaeva amounted to 2106/ml, cell viability staining Trifanova blue 98%.Lymphocytes were incubated in medium RPMI-1640 (Flow) supplemented with 5% fetal calf serum (Flow), 2 mm L-glutamine (Flow), 40 µg/ml gentamicin ("Pharmachem") and 5 mm HEPES-buffer for 2 hours at Ntrolle used saline solution in an appropriate amount.The level of expression of differencirovannyh antigens was evaluated in the reaction of indirect immunofluorescence using monoclonal antibodies anti-D21, anti-D22 and anti-IgM. As secondary antibodies used antibody labeled with FITZ ("Sorbent", ,Moscow).Registration green fluorescence FITZ was performed using microscope EU Lumam-RPO 11" (eyepiece X3, lens h) when counting at least 200 cells in the preparation.In patients with burns compared with healthy donors significantly reduced the number of cells that carry on their surface differencirovanie antigens CD21 (from 8.9 0.8 to 5,9 0,9%), CD22 (from 9.9 0.9 to 5,6 1,1%) and IgM (from 7.9 0.5 to 4,7 0,6 %). During the incubation of lymphocytes burn patients with peptide Tyr-Glu-Gly was significantly increased number Mature B-lymphocytes expressing differencirovanie antigens CD21, CD22 and IgM, respectively 8,6 0,6% (p<0,01), 9,0 0,8% (p<0.01) and 7,2 0,6% (p<0,01).On day 19 of incubation, the embryos broiler chickens breed "Livorno" were subjected to surgical bursectomy in aseptic conditions. At the same time control groupenum removal of the Bursa fabritsiusa.Starting from 4 weeks of age during the week bursectomised chickens 1 time per day intramuscularly injected with a peptide Tyr-Glu-Gly dose of 0.1 mg/kg of body weight. The control were bursectomised chickens that received saline in the same volume.Evaluation of the effectiveness antigennegative differentiation of b-lymphocytes in experimental animals produced in the reaction by indirect membrane immunofluorescence assay using antibody to chicken IgG and light chains of chicken immunoglobulins (Sigma, Sweden). To do this, the birds at the end of treatment were taken blood stabilized with heparin (25 U/ml). Forth from heparinised peripheral blood lymphocytes were isolated by centrifugation on a density gradient ficoll-urografin. The obtained cells are washed three times with medium 199 without calcium ions at 37oC. cell Viability test with absorption Trypanosoma blue was 96-98%. Then cells were incubated with monoclonal antibodies against IgG and light chains of immunoglobulins chickens at a temperature of 37oC for 30 minutes. After that, cells are washed three times by PBS, incubated with FITZ-labeled antibodies (Sigma, Sweden) for 30 minutes at 4oC, osmyslennym microscope "EU Lumam-RPO 11". Each drug was calculated from 200 to 500 cells.If bursectomy observed a significant decrease in the number of total sIg+cells and sIgG+cells. So lonaprisan and embryonic bursectomised birds the number of cells bearing surface IgG, was 9.6 0.9 and 3,4 0,5% (p<0.01), and total Ig of 19.1 and 1,1 8,7 0,5% (p<0,01), respectively. It is established that the introduction of the peptide Tyr-Glu-Gly bursectomised chickens increases the number of Mature B-lymphocytes with immunoglobulin receptors. The number sIgG+cells were increased from 3.4 to 0.5 in the control to 7.8 0.6% in experience (p<0.01) and the number of sIg+cells from 8.7 0.5 to 14,6 0,7% (p<0,01), approaching normal levels, although not reaching them.In comparison with the known means Lis-His-Gly-NH2(prototype) of the claimed peptide Tyr-Glu-Gly able to stimulate antigennegative differentiation of B-lymphocytes at doses 10 times smaller, which indicates its higher specific activity. Reducing the dosage of the peptide to achieve the same effect makes it possible to reduce the risk of side effects.Thus, in experimental study of the specific activity of the claimed substance found that Tr is>Sources of information
1. Samoilova, R. S. the Ontogeny of normal B-lymphocytes person // Hematol. and transfusion. - 1993. - #4. - S. 18-22.2. Burrows, P. D., Cooper M. D. B cell development and differentiation // Curr. Opin. Immunol. - 1997. - Vol. 9 - N 2 - pp. 239-244.3. Brand , A., Gilmour D. G., Goldstein G. Lymphocyte-differentiating hormone of bursa of Fabricius // Science. - 1976. - Vol. 193. - P. point of 319-321.4. Goldstein G. , Scheid, M., Boyse, E. A. et al. Thymopoietin and bursopoietin: induction signals regulating early lymphocyte differentiation // Cold Spring Harb. Symp. Quant. Biol., - 1977. - N 41. - P. 5-8.5. USSR author's certificate N 1438044, MKI5A 61 K 39/00, 1985.6. Stepanov A. C. Polypeptide factors of handbags fabritsiusa and their impact on immunogenesis and hemostasis: author. dis. Kida. the honey. Sciences. - Chita, 1988. - 22 S.7. U.S. patent N 5264418, MKI5C 07 K 3/20, 1993.8. U.S. patent N 4584284, MKI4A 61 K 37/24; C 07 K 5/08; C 08 F 283/00, 1986.9. Kolker, I. I., S. Vishnevskaya, M., Panov, Y. M. and other T - and B-lymphocytes in patients with thermal burns // Clinically. medicine. - 1985. - N 7. - S. 87-93.10. Belotsky S. M., Borisova, So, Shastina T. I. and other Characteristics of phagocytes, T - and B-lymphocytes in annealed // Immunology. - 1983. - N-6. - S. 51-54.11. Jalkanen, S., Granfors K., Jalkanen M. et al. Immune capacity of the chicken bursectomized at 60 hr of incubation: surface immunoglobulin and B-L (Ia-like antigen-bearing cells // J. Immunol. - 1983. - Vol. 130. - N of the peptide of the formula Tyr-Glu-Gly (L-tyrosyl-L-glutamyl-L-glycine) as a means of stimulating antigennegative differentiation of B-lymphocytes.
FIELD: medicine, immunology, peptides.
SUBSTANCE: invention relates to a new composition of biologically active substances. Invention proposes the composition comprising of peptides of the formula: Arg-Gly-Asp and H-Tyr-X-Y-Glu-OH wherein X means Gln and/or Glu; Y means Cys(acm) and/or Cys that elicits ability to inhibit the proliferative response for phytohemagglutinin, to induce the suppressive activity of mononuclear cells and ability of peptides to induce secretion of immunosuppressive cytokines of grouth-transforming factor-β1 and interleukin-10 (IL-10). The composition can be prepared by a simple procedure.
EFFECT: valuable biological properties of composition.
3 cl, 16 tbl, 9 ex
FIELD: organic chemistry, medicine.
SUBSTANCE: invention represents ligands MC-4 and/or MC-3 of the formula (I): , wherein X means hydrogen atom, -OR1, -NR1R1' and -CHR1R1' wherein R1 and R1' are taken among the group: hydrogen atom, (C1-C6)-alkyl and acyl; (1) each R2 is taken independently among the group: hydrogen atom, (C1-C6)-alkyl; or (2) (a) R2 bound with carbon atom that is bound with X and Z1 and substitute R5 can be optionally bound to form carbocyclic or heterocyclic ring that is condensed with phenyl ring J; or (b) R2 bound with carbon atom that is bound with ring Ar can be bound with R7 to form ring condensed with ring Ar; each among Z1, Z2 and Z3 is taken independently from the following groups: -N(R3e)C(R3)(R3a)-, -C(R3)(R3a)N(R3e)-, -C(O)N(R3d)-, -N(R3d)C(O)-, -C(R3)(R3a)C(R3b)(R3c)-, -SO2N(R3d)- and -N(R3d)SO2- wherein each among R3, R3a, R3b and R3c, R3d, R3e when presents is taken independently among hydrogen atom and (C1-C6)-alkyl; p is a whole number from 0 to 5 wherein when p above 0 then R4 and R4' are taken among hydrogen atom, (C1-C6)-alkyl and aryl; R5 represents 5 substitutes in phenyl ring J wherein each R5 is taken among hydrogen atom, hydroxy-, halogen atom, thiol, -OR12, -N(R12)(R12'), (C1-C6)-alkyl, nitro-, aryl wherein R12 and R12' are taken among hydrogen atom and (C1-C6)-alkyl; or two substitutes R5 can be bound optionally to form carbocyclic or heterocyclic ring that is condensed with phenyl ring J; q = 0, 1, 2, 3, 4 or 5 wherein when q above 0 then R6 and R6' are taken among hydrogen atom and (C1-C6)-alkyl; Ar is taken among the group consisting of phenyl, thiophene, furan, oxazole, thiazole, pyrrole and pyridine; R7 are substitutes at ring Ar wherein each R7 is taken among hydrogen, halogen atom, -NR13R13', (C1-C6)-alkyl and nitro- wherein R13 and R13' are taken among hydrogen atom and (C1-C6)-alkyl; r is a whole number from 0 to 7 wherein when r is above 0 then R8 and R8' are taken among hydrogen atom and (C1-C6)-alkyl; B is taken among -N(R14)C(=NR15)NR16R17, -NR20R21, heteroaryl ring and heterocycloalkyl ring wherein R14-R17, R20 and R21 are taken independently among hydrogen atom and (C1-C6)-alkyl; s = 0, 1, 2, 3, 4 or 5 wherein when s is above 0 then R and R9' are taken among hydrogen atom and (C1-C6)-alkyl; R10 is taken among the group consisting of optionally substituted bicyclic aryl ring and optionally substituted bicyclic heteroaryl ring; D is taken among hydrogen atom, amino- and -C(O)R11 wherein R11 is taken among the following group: hydroxy-, alkoxy-, amino-, alkylamino-, -N(R19)CH2C(O)NH2 wherein R19 represents (C1-C6)-alkyl, -NHCH2CH2OH and -N(CH3)CH2CH2OH, or its isomers, salts, hydrates or biohydrolysable ester, amide or imide.
EFFECT: valuable medicinal properties of compounds.
18 cl, 107 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: it is suggested to apply Pro-Gly-Pro tripeptide known as anticoagulant to keep stable norglycemia and stable normoinsulinemia in circulation at no side effects because the above-mentioned tripepetide is being natural human and animal metabolite.
EFFECT: higher efficiency of application.
3 cl, 5 ex, 2 tbl
SUBSTANCE: the set of components is suggested containing: (a) pharmaceutical preparation including low-molecular thrombin inhibitor or its pharmaceutically acceptable derivative in the mixture with pharmaceutically acceptable adjuvant, solvent or carrier; and (b) pharmaceutical preparation including pre-medicine of low-molecular thrombin inhibitor or pharmaceutically acceptable derivative of this pre-medicine in the mixture with pharmaceutically acceptable adjuvant, solvent or carrier, where components (a) and (b), each of them, should be taken in the form suitable to be introduced together; it is, also, suggested to apply this set of components for treating the state at which it is necessary or preferably to inhibit thrombin. The innovation enables to treat thrombotic states such as thrombosis of deep veins and pulmonary embolism.
EFFECT: higher efficiency of application.
30 cl, 1 tbl
FIELD: medicine, experimental medicine.
SUBSTANCE: one should introduce tripeptide Pro-Gly-Pro for laboratory animals as injections at the quantity of 0.09-1.0 mg/kg body weight, and, also, gelatin as fodder additive. The method suggested enables to suppress appetite, decrease the quantity of fodder intake that leads to decreased body weight as a result.
EFFECT: higher efficiency.
2 cl, 5 dwg, 5 ex
FIELD: medicine, chemistry of peptides, amino acids.
SUBSTANCE: invention relates to novel biologically active substances. Invention proposes the novel composition comprising peptides of the formula: H-Arg-Gly-Asp-OH and H-Tyr-X-Y-Glu-OH wherein X means Gln and/or Glu; Y means Cys(acm) and/or Cys. The composition shows ability to inhibit proliferative activity of mononuclear cells, to induce suppressive activity and their ability for secretion of cytokines TNF-1β (tumor necrosis factor-1β) and IL-10 (interleukin-10 ).
EFFECT: simplified method for preparing composition, valuable medicinal properties of composition.
4 cl, 16 tbl, 9 ex
SUBSTANCE: invention relates to a method for preparing foodstuff containing hypotensive peptides and it using as an anti-hypertensive agent that can be used as a foodstuff. Method involves stages for fermentation of casein-containing fermenting material with lactobacillus microorganism, nanofiltration of the prepared peptide-containing fermentation product and isolation of the product. Prepared product is used as an anti-hypertensive agent and as a foodstuff also. Invention provides preparing a foodstuff with the high content of hypotensive peptides enriched by bivalent ions.
EFFECT: improved preparing method of foodstuff.
22 cl, 1 dwg, 4 ex
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to medicinal agent used for correction of metabolic vascular syndrome and diseases accompanying with vascular wall penetrability disorder and capillaries fragility and can be used as agent enhancing resistance of capillaries. Invention proposes peptide lysyl-glutamyl-aspartic acid of the general formula: H-Lys-Glu-Asp-OH corresponding to the sequence 1 [SEQ ID NO:1] possessing biological activity and eliciting enhancing effect on resistance of capillaries. Also, invention proposes pharmaceutical composition enhancing resistance of capillaries and containing effective amount of peptide lysyl-glutamyl-aspartic acid of the general formula: H-Lys-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] as an active component and a pharmaceutically acceptable carrier. Pharmaceutical composition is prepared in form suitable for parenteral administration. Also, invention proposes a method for prophylaxis and/or treatment of microcirculation disorders in organs and tissues and involves administration in patient pharmaceutical composition containing effective amount of peptide lysyl-glutamyl-aspartic acid of the general formula: H-Lys-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] as an active component in the dose 0.01-100 mcg/kg of body mass for at least once per a day for period necessary for providing the therapeutic effect. Administration is carried out by parenteral route. Proposed group of inventions provides preparing a novel peptide possessing biological activity eliciting in enhancing resistance of capillaries and using this peptide for preparing pharmaceutical composition enhancing resistance of capillaries.
EFFECT: enhanced and valuable medicinal properties of peptide and pharmaceutical composition.
7 cl, 3 tbl, 2 dwg, 6 ex
FIELD: peptides, medicine, hepatology, pharmacy.
SUBSTANCE: groups of inventions relates to medicinal agents used in treatment of liver diseases. Invention proposes a pharmaceutical composition stimulating regeneration of liver tissue and comprising the effective amount of peptide glutamyl-aspartyl-leucine as an active component of the general formula: H-Glu-Asp-Leu-OH of the sequence 1 [SEQ ID NO:1] and a pharmaceutically acceptable carrier. Invention proposes peptide glutamyl-aspartyl-leucine of the general formula: H-Glu-Asp-Leu-OH of the sequence 1 [SEQ ID NO;1] stimulating regeneration of liver tissue. Also, invention proposes a method for stimulating liver tissue involving administration in a patient a pharmaceutical composition containing peptide glutamyl-aspartyl-leucine of the general formula: H-Glu-Asp-Leu-OH of the sequence 1 [SEQ ID NO:1] as an active component used in the dose 0.01-100 mcg/kg of body mass for at least once per a day for period required for appearance of the therapeutic effect. Invention provides the development of peptide possessing the biological activity eliciting in stimulating regeneration of liver tissue, and pharmaceutical composition containing this peptide as an active component. Using this composition stimulates regeneration of liver tissue based on recovery of synthesis of tissue-specific proteins and normalization of functions of liver cells.
EFFECT: valuable properties of peptide and pharmaceutical composition.
7 cl, 5 tbl, 1 dwg, 6 ex
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to drugs used in prophylaxis and treatment of the locomotor system, in particular, degenerative-dystrophic joint and backbone diseases. Invention proposes a pharmaceutical composition normalizing metabolism in osseous and cartilage tissues and comprising the effective amount of peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] as an active component, and pharmaceutically acceptable carrier. Invention proposes peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] possessing the biological activity manifesting as normalization of metabolism in osseous and cartilage tissues. Invention proposes a method for prophylaxis and treatment of locomotor system by normalization of metabolism in osseous and cartilage tissues involving administration in a patient of a pharmaceutical composition containing as an active component peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] in the dose 0.01-100 mcg/kg of the body mass for at least once per a day for time necessary for achievement of the therapeutic effect. Invention can be used as agent normalizing metabolism in osseous and cartilage tissues.
EFFECT: valuable medicinal properties and high effectiveness of peptide and pharmaceutical composition.
6 cl, 2 tbl, 1 dwg, 1 ex